98
Participants
Start Date
January 31, 2012
Primary Completion Date
May 31, 2016
Study Completion Date
December 31, 2016
H+CT
All patients were treated with trastuzumab plus chemotherapy as the first-line therapy. There were no protocol-specified chemotherapy regimens. This is a prospective observational study. Efficacy and safety of trastuzumab were analyzed, clinical and pathological data were collected to evaluate the potential prognostic factors on progressive free survival.
Zhongshan Hospital Affiliated to Fudan University, Shanghai
Shanghai Zhongshan Hospital
OTHER